5 Healthcare and Software Stocks to Buy According to Michel Massoud’s Melqart Asset Management

2. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Melqart Asset Management’s Stake Value: $162.654 million

Percentage of Melqart Asset Management’s 13F Portfolio: 7.3%

Number of Hedge Fund Holders: 69

Founded in 2017 and headquartered in Boston, Massachusetts, Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) deals with treatments for rare diseases. By the end of the second quarter of 2021, Melqart Asset Management owned 885,384 shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) worth over $162 million, which comprised 7.3% of the fund’s portfolio.

On July 21, AstraZeneca plc (NYSE:AZN) announced its acquisition of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for $13.3 billion.

ClearBridge Investments, an investment management firm, mentioned Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) in its “Large Cap Growth Strategy” first quarter 2021 investor letter and shared its insights on the company. Here is what the fund said about Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) in its Q1 2021 investor letter:

“We also sold biotechnology holding Alexion Pharmaceuticals ahead of its acquisition by AstraZeneca but expect to redouble our efforts in health care through the rest of the year. We see good growth potential in the sector and after full due diligence, have been busy populating our wish list with new names we would like to own.”